52,745 Shares in Boston Scientific Corporation $BSX Bought by Callan Family Office LLC

Callan Family Office LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 52,745 shares of the medical equipment provider's stock, valued at approximately $2,251,000.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Boston Scientific in the second quarter worth approximately $5,534,781,000. Norges Bank acquired a new stake in shares of Boston Scientific in the 4th quarter valued at $2,199,395,000. Bank of New York Mellon Corp bought a new stake in Boston Scientific in the second quarter worth $339,031,000. Deutsche Bank AG acquired a new position in Boston Scientific during the second quarter worth $254,247,000. Finally, Assenagon Asset Management S.A. increased its position in Boston Scientific by 133.6% during the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider's stock worth $631,135,000 after buying an additional 5,751,760 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Insiders Place Their Bets

In other news, CEO Michael F. Mahoney acquired 186,240 shares of the firm's stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares of the company's stock, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger acquired 2,100 shares of the company's stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director owned 17,160 shares of the company's stock, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have bought 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BSX shares. Stifel Nicolaus set a $60.00 price target on Boston Scientific in a research report on Wednesday, July 29th. Oppenheimer lowered their price objective on Boston Scientific from $90.00 to $85.00 and set an "outperform" rating on the stock in a report on Monday, July 27th. Zacks Research downgraded Boston Scientific from a "hold" rating to a "strong sell" rating in a research note on Friday, June 5th. Argus restated a "hold" rating on shares of Boston Scientific in a report on Friday, July 31st. Finally, TD Cowen decreased their target price on Boston Scientific from $61.00 to $56.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $71.62.

Boston Scientific Stock Up 2.1%

Shares of NYSE BSX opened at $50.39 on Friday. The stock has a market cap of $73.03 billion, a PE ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56. The business has a fifty day moving average of $46.34 and a two-hundred day moving average of $57.86. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source